Fig. 3: Competitive transduction assay to compare efficiency of barcoded rAAV promoters in rats. | Gene Therapy

Fig. 3: Competitive transduction assay to compare efficiency of barcoded rAAV promoters in rats.

From: High-throughput evaluation of cardiac-specific promoters for adeno-associated virus mediated cardiac gene therapy

Fig. 3: Competitive transduction assay to compare efficiency of barcoded rAAV promoters in rats.The alternative text for this image may have been generated using AI.

SD rats (6–8 week male) were injected with a rAAV promoter kit packaged in AAV6 (n = 5) and AAV9 (n = 4) at 5 × 1011 vg via the tail vein. Four weeks post transduction, rats were sacrificed. A Heart and B liver tissues were collected for DNA/RNA extraction followed by NGS analysis. For each capsid and tissue combination, results on the left are displayed as boxplots comparing performance of ubiquitous promoter CMV, liver-specific promoter (LSP) and cardiac-specific promoters (CSP), and on the right as boxplots comparing performance of cardiac-specific promoters only. Statistical analyses were performed using the Kruskal-Wallis test followed by Dunn’s post-hoc test with Bonferroni correction (*p < 0.05).

Back to article page